Chantal Meeuwisse, Amgen
At Amgen, our mission is to serve patients, focusing on serious, life-interrupting illnesses. Amgen is one of the world’s leading biotechnology companies. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives.
Amgen was founded in 1980 and since then has grown to be one of the world’s leading independent biotechnology companies. We have a presence in approximately 100 countries worldwide, whereby we focus on six therapeutic areas: oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
Our Nordic & Baltics headquarters is based in Stockholm, from where we provide centralized hub support within the region.
My role is focused first of all on Finance. Ensuring we are compliant with rules and regulations and have sound financial planning & monitoring mechanisms in place, as well as creating a financial outlook for both the short and long-term.
On top of that I am also responsible for what we call Sales & Marketing Effectiveness. In a nutshell this is any support that helps our countries drive their business locally. It varies from sales analysis, customer targeting, customer engagement channels and investments, as well as providing technology and support to the people in the field. In addition I am also responsible for Logistics & Pricing to ensure that our products are distributed in a proper and timeline manner, in line with the contractual agreements.
I got acquainted with the Dutch Chamber when a business relationship invited me to the “Back 2 work” mingle, end of August that was organised by both the Dutch and Swedish Chamber.
After different conversations with a variety of people and attending the Forum for Health Policy, organised in September, we decided to join the Dutch Chamber.
To face similar challenges
Based upon the experience so far I believe our membership of the Dutch Chamber can provide additional
relationships for Amgen, as well as meeting up with other stakeholders that face similar challenges as Amgen. We hope that we can jointly discuss these to create a common understanding and hopefully also find solutions. From a personal point of view I also look forward to meet interesting new people.